Abstract
A galactose breath test that quantitates [1-13C]galactose conversion to 13CO2 provides information on the whole body galactose oxidative capacity. As there is little information on the relationship between whole body oxidation and the genotype in patients with galactosemia, we measured the 13CO2 excretion for 2 h after administration of [1-13C]galactose in 37 patients (3–48 y old) with galactose-1-phosphate uridyltransferase (GALT) deficiency and 20 control subjects (3–37 y old). Eleven patients with the common Q188R/Q188R genotype and no detectable erythrocyte GALT activity eliminated <2% of a bolus of [1-13C]galactose as 13CO2 compared with 8.47 to 28.23% in controls. This defines a severe metabolic phenotype. Seven patients with one Q188R allele and a second mutant allele such as L195P, E308K, V151A, M142K, or Q344K and one patient with a K285N/unknown genotype also released <2% as 13CO2 in 2 h. The presence of N314D or S135L as the second mutant allele does not impair total body galactose oxidation, as individuals with the GALT genotype of Q188R/N314D, K285N/N314D, and Q188R/S135L had normal 2-h galactose breath tests. Subjects with S135L/S135L, N314D/N314D, S135L/ΔT2359 as well as other rarer genotypes such as R258C/Y209C, E203 K/IVSC-N314D, K285N/T138M, Q188R/D113N, S135L/F171S, R148W/N314D, and IVSC-N314D/N314D oxidized galactose comparable to controls. The dissociation of residual erythrocyte GALT activity and whole body galactose oxidative capacity is exemplified by blacks with a S135L/S135L genotype and absent erythrocyte GALT activity. An oral 2-h [1-13C]galactose breath test distinguishes severe and variant GALT genotypes and enables delineation of the extent of impaired galactose metabolism in an array of patients who possess diverse GALT mutations. It may prove to be useful in establishing whether a patient is capable of manifesting disease similar to patients with a Q188R/Q188R genotype.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- GALT:
-
galactose-1-phosphate uridyltransferase
- BMR:
-
basal metabolic rate
- CUMPCD:
-
cumulative percent of the dose, PO, oral
References
Segal S, Berry GT 1995 Disorders of galactose metabolism. In: Scriver CH, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Diseases, 7th Ed, Vol I. McGraw-Hill, New York, 967–1000.
Elsas LJ, Langley S, Steele E, Evinger J, Fridovich-Keil JL, Brown A, Singh R, Fernhoff P, Hjelm LN, Dembure PP 1995 Galactosemia: a strategy to identify new biochemical phenotypes and molecular genotypes. Am J Hum Genet 56: 630–639.
Elsas LJ, Langley S, Paulk EM, Hjelm LN, Dembure PP 1995 A molecular approach to galactosemia. Eur J Pediatr 154: S21
Baker L, Mellman WJ, Tedesco TA, Segal S 1966 Galactosemia: symptomatic and asymptomatic homozygotes in one Negro sibship. J Pediatr 68: 551–558.
Mason HH, Turner ME 1935 Chronic galactosemia, report of case with studies on carbohydrates. Am J Dis Child 50: 359–374.
Lai K, Langley SD, Singh RH, Dembure PP, Hjelm LN, Elsas LJ 1996 A prevalent mutation for galactosemia among black Americans. J Pediatr 128: 89–95.
Landt M, Ritter D, Lai K, Benke PJ, Elsas LJ, Steiner RD 1997 Black children deficient in galactose-1-phosphate uridyltransferase: correlation of activity and immunoreactive protein in erythrocytes and leukocytes. J Pediatr 130: 972–980.
Beutler E, Baluda MC, Sturgeon P, Day RW 1965 A new genetic abnormality resulting in galactose-1-phosphate uridyltransferase deficiency. Lancet 1: 353
Elsas LJ, Dembure PP, Langley S, Paulk EM, Hjelm LN, Fridovich-Keil JL 1994 A common mutation associated with the Duarte galactosemia allele. Am J Hum Genet 54: 1030–1036.
Lin HC, Kirby LT, Ng WG, Reichardt JKV 1994 On the molecular nature of the Duarte variant of galactose-1-phosphate uridyltransferase (GALT). Hum Genet 93: 167–169.
Lai K, Langley SD, Dembure PP, Hjelm LN, Elsas LJ 1998 Duarte allele impairs biostability of galactose-1-phosphate uridyltransferase in human lymphoblasts. Hum Mutat 11: 28–38.
Langley SD, Lai K, Dembure PP, Hjelm LN, Elsas LJ 1997 Molecular basis for Duarte and Los Angeles variant galactosemia. Am J Hum Genet 60: 366–372.
Elsas LJ, Lai K 1998 The molecular biology of galactosemia. Genetics Med 1: 40–48.
Berry GT, Nissim I, Mazur AT, Elsas LJ, Singh RH, Klein PD, Gibson JB, Lin Z, Segal S 1995 In vivo oxidation of [1-13C]galactose in patients with galactose-1-phosphate uridyltransferase deficiency. Biochem Mol Med 56: 158–165.
Berry GT, Nissim I, Gibson JB, Lin Z, Elsas LJ, Singh RH, Klein PD, Segal S 1997 Quantitative assessment of whole body galactose metabolism in galactosemic patients. Eur J Pediatr 156: S43
Segal S, Cuatrecasas P 1968 The oxidation of 14C-galactose by patients with congenital galactosemia: evidence for a direct oxidative pathway. Am J Med 44: 340–347.
Segal S, Rogers S, Holtzapple PG 1971 Liver galactose-1-phosphate uridyltransferase: activity in normal and galactosemic subjects. J Clin Invest 50: 500–506.
Schoeller DA, Klein PD 1979 A microprocessor controlled mass spectrometer for the fully automated purification and isotopic analysis of breath carbon dioxide. Biomed Mass Spectrom 6: 350–355.
Schofield WN 1985 Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39C: 5
de Weir JR 1949 New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109: 1–9.
Elsas LJ, Ellerine NP, Klein PD 1993 Practical methods to estimate whole body leucine oxidation in maple syrup urine disease. Pediatr Res 33: 445–451.
Rogers S, Holtzapple PG, Mellman WJ, Segal S 1970 Characteristics of galactose-1-phosphate uridyltransferase in intestinal mucosa of normal and galactosemic humans. Metabolism 19: 701–708.
Segal S, Blair A, Topper YJ 1962 Oxidation of 14C labeled galactose by subjects with congenital galactosemia. Science 136: 150–151.
Acknowledgements
The authors thank S.D. Langley, L.N. Hjelm, P.P. Dembure, and K. Muvaledharan for molecular screening and sequencing of GALT genes and the nursing staff of the GCRC of both institutions.
Author information
Authors and Affiliations
Additional information
Supported by grants from the National Institutes of Health, PO1-HD29847, MO1 RR 00240, and MO1 RR 0039, and by the Diasorin-Meretek Breath Test Group.
Rights and permissions
About this article
Cite this article
Berry, G., Singh, R., Mazur, A. et al. Galactose Breath Testing Distinguishes Variant and Severe Galactose-1-Phosphate Uridyltransferase Genotypes. Pediatr Res 48, 323–328 (2000). https://doi.org/10.1203/00006450-200009000-00010
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200009000-00010
This article is cited by
-
Arginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia
Orphanet Journal of Rare Diseases (2018)
-
Galactosemia in the Turkish population with a high frequency of Q188R mutation and distribution of Duarte-1 and Duarte-2 variations
Journal of Human Genetics (2013)
-
Introduction to the Maastricht workshop: lessons from the past and new directions in galactosemia
Journal of Inherited Metabolic Disease (2011)
-
Negative screening tests in classical galactosaemia caused by S135L homozygosity
Journal of Inherited Metabolic Disease (2009)
-
The clinical and molecular spectrum of galactosemia in patients from the Cape Town region of South Africa
BMC Pediatrics (2002)
